Table 2.
Distribution of Patients with Deletion 5q by FAB, IPSS, and percent of marrow blasts
| No. (%) of Row | ||||||
|---|---|---|---|---|---|---|
| A. FAB Group | Alone (n=65) |
+1 Abn (n=32) |
+2 Abn (n=17) |
+ ≥3 Abn (n=74) |
+ 7 Chromosome Abn (n=99) |
Total (n=287) |
| RA | 33 (45) | 9 (12) | 7 (10) | 12 (16) | 13 (18) | 74 (26) |
| RA – RS | 6 (24) | 4 (16) | 3 (12) | 3 (12) | 9 (36) | 25 (9) |
| RAEB | 23 (16) | 17 (12) | 5 (4) | 47 (33) | 49 (35) | 141 (49) |
| RAEBT | 1 (3) | 1 (3) | 1 (3) | 11 (30) | 23 (62) | 37 (13) |
| CMML | 2 (20) | 1 (10) | 1 (10) | 1 (10) | 5 (50) | 10 (4) |
| B. IPSS Risk * | ||||||
| Low | 25 (93) | 2 (7) | 0 | 0 | 0 | 27 (9) |
| Intermediate 1 | 30 (46) | 17 (26) | 7 (11) | 6 (9) | 6 (9) | 66 (23) |
| Intermediate 2 | 10 (8) | 11 (8) | 9 (7) | 42 (32) | 61 (46) | 133 (46) |
| High | 0 | 2 (3) | 1 (2) | 26 (43) | 32 (53) | 61 (21) |
| C. Percent Marrow Blasts | ||||||
| 0–4 | 41 (36) | 15 (13) | 11 (10) | 21 (28) | 27 (24) | 115 (40) |
| 5–9 | 12 (15) | 9 (11) | 3 (4) | 22 (27) | 37 (45) | 83 (29) |
| 10–19 | 12 (14) | 8 (9) | 3 (3) | 31 (35) | 35 (39) | 89 (31) |
*
Patients with prior therapy were classified by their IPSS risk group at the time of referral; abn=abnormality